Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial.

@article{Genevay2012AdalimumabIA,
  title={Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial.},
  author={St{\'e}phane Genevay and Axel Finckh and Pascal Zufferey and Sebastien Viatte and Federico Balagu{\'e} and Cem Gabay},
  journal={Annals of the rheumatic diseases},
  year={2012},
  volume={71 4},
  pages={560-2}
}
INTRODUCTION Two subcutaneous injections of adalimumab in severe acute sciatica significantly reduced the number of back operations in a short-term randomised controlled clinical trial. OBJECTIVE To determine in a 3-year follow-up study whether the short-term benefit of adalimumab in sciatica is sustained over a longer period of time. METHODS The primary outcome of this analysis was incident discectomy. Three years after randomisation, information on surgery could be retrieved in 56/61… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS